Alsteni Medical is commercializing a groundbreaking medical device that enables patient-controlled appetite suppression by triggering the body's natural hormonal responses, including GLP-1 and other appetite-suppressing hormones. This device is the result of 20 years of clinical research and frontline obesity treatment experience at USC for weight management. Alsteni Medical was co-founded by Nicholas Demetriades.